Yucca

Yucca (Yucca schidigera and Related Species): A Comprehensive Reference

1. Identity and Botanical Classification

Taxonomy and Common Names

The Yucca genus belongs to the Agavoideae subfamily and encompasses about 40 to 50 species, most of which are native to southern North America. As one of the major industrial sources of steroid saponins, Yucca schidigera Roezl (Agavaceae family) is a plant native to the desert of the southwestern United States and northern Baja California, Mexico. Also known as Mojave yucca or Spanish dagger, Y. schidigera is a hearty, drought-tolerant, evergreen plant that thrives in full sun and little water, growing in a variety of terrain including rocky desert slopes and desert flats, reaching up to 16 feet tall and 10 feet wide.

Yucca schidigera is a member of the Asparagaceae family, which includes agave and asparagus species. The most commonly referenced species in commercial and medicinal contexts include Yucca filamentosa, Yucca brevifolia (Joshua tree), Yucca aloifolia (Spanish bayonet), and Yucca gloriosa (Spanish dagger). Common synonyms and trade names include Mohave yucca, Adams needle, aloe yucca, bear grass, dagger plant, soapweed, Our Lord's candle, and Spanish bayonet.

The yucca was first described by Swedish botanist Carl Linnaeus in the 1750s in his taxonomy of plant and animal species, though it was being used by Native Americans long before that.

Commercial Forms and Preparations

Two major commercial products of yucca are available on the market: dried and finely powdered logs (yucca powder) or mechanically pressed and thermally condensed juice (yucca extract). Commercially, Y. schidigera extracts are produced from pressed and dejuiced trunk and flowering stems, or as dried powder from unprocessed yucca. These products possess the GRAS (Generally Recognized as Safe) label, which allows their use as a foaming agent in soft drinks (including root beer), pharmaceutical, cosmetic, food, and feeding-stuff industries.

Whole yucca plant powder in tablet form is a common nutraceutical preparation. Currently, Y. schidigera products are used as flavorings and foaming agents in soft drinks and foods, as surfactants and preservatives in cosmetics, as nutraceuticals, as biopesticides and fertilizers for crops, and as animal feed additives.

2. Traditional and Historical Use

Native American and Indigenous Uses

Indigenous populations of the Americas have used yucca for fibers, soap, food, and medicine for millennia, using it to treat a variety of ailments including gonorrhea, arthritis, rheumatism, hair loss, and dandruff. The yucca features prominently in indigenous folklore and ceremony, particularly for populations of today's Southwestern United States.

Some species, such as Yucca schidigera, were used for bowstrings, nets, ropes, mats, sandals, and clothing. The plant was also used as food; for example, in eastern Costa Rica there is a tradition of eating the Itabo flower (Yucca elephantipes) at Easter. Most importantly, these species have been used in traditional medicine. The Cheyenne cultures used Yucca glauca to stimulate hair growth and in skin conditions, while New Mexico healers used it to treat asthma and headaches.

Navajos used the yucca root as a soap, pounding the dry roots and whisking them into cold water to create a soapy lather for cleaning clothes, hair, and themselves. Yucca suds were also used in Native American rituals involving spiritual cleansing. Yucca root was used as a soap and shampoo; a poultice of roots and leaves was applied to treat insect bites; the raw fruit was noted for its laxative effect; and the trunk was used to make a tobacco mix and a sore throat chew. The plant was also used ceremonially in fertility rites.

Native American tribes in the Southwestern United States and Northern Mexico found numerous uses for yucca. Among the most common was hygiene — the roots of Yucca baccata were pounded to remove extracts that were made into shampoo and soap. This plant was used in traditional medicine by Native Americans to treat a variety of ailments including arthritis.

More modern ethnobotanical documentation records its use to treat asthma, rheumatism, gonorrhea, sunburns, and arthritis. Starting in 1975, yucca extracts began to be formally tested as a treatment to manage arthritis.

Food Use

Yucca was a very important plant to traditional Southwest Indian life. Yucca fruits and roots were eaten, and the tough yucca fiber was used to weave baskets and sandals. Yucca leaves are also used ceremonially by the Navajos. Archaeologists have discovered bundles of prepared yucca leaves, called "quids," in prehistoric structures, indicating that the use of yucca leaves for this purpose dates back to ancient times.

3. Key Constituents and Active Compounds

Steroidal Saponins

Yucca schidigera is one of the major commercial sources of steroidal saponins. The activity of commercial Y. schidigera products is related to the presence of yucca steroidal saponins (furostanol- and spirostanol-types), accounting for about 10% of the dry weight. The primary saponin aglycones found in yucca material are sarsasapogenin and smilagenin.

From a saponin fraction of the stems of Yucca schidigera, a number of new anti-yeast monodesmosidic spirostanol saponins named schidigera-saponins A1, A2, A3, B1, C1, C2, D1, D2, D3, D4, D5, E1, F1, and F2 were isolated, together with several related known saponins. Additional isolates include novel furostanol glycosides; on the basis of extraction efficiency, furostanol glycosides made up only 6.8% of total saponins isolated.

As one of the secondary metabolites, spirostanol saponins have been found to have broad bioactivities, such as antiproliferative, anti-inflammatory, anti-HIV, anti-bacterial, anti-fungi, and anti-hyperuricemic activities.

Polyphenols and Stilbenes

Five phenolic constituents have been identified in Yucca schidigera bark, including two known stilbenes — trans-3,4',5-trihydroxystilbene (resveratrol) and trans-3,3',5,5'-tetrahydroxy-4'-methoxystilbene — as well as three novel compounds, yuccaols A, B, and C, with spiro-structures rarely occurring in the plant kingdom. Two additional novel phenolic constituents with unusual spiro-structures, yuccaols D and E, were subsequently isolated from the methanol extract of Yucca schidigera bark.

Y. schidigera contains a number of unusual polyphenols — derivatives of resveratrol and naringenin — called spiro-flavostilbenoids, which have potent in vitro anti-inflammatory, antioxidant, and moderate cholinesterase inhibitory activities. Other identified phenolics include resveratrol, quercetin, the spirobiflavonoid larixinol, and yuccaols A–E, along with the compound yuccaone A.

Other Constituents

The saponins are natural detergents that form stable foams, which contain both fat- and water-soluble components. As much as 10% of the yucca stem contains saponins, making it one of the richest plant sources. The positive effects of dietary supplementation with yucca products on growth rates, feed efficiency, and health appear to be due not only to the saponin constituents but also to other constituents. In addition to saponins and polyphenols, Yucca schidigera also contains polysaccharides that contribute to its surface-active properties.

4. Mechanisms of Action

Anti-inflammatory Mechanisms

Yucca is a rich source of polyphenolics, including resveratrol and other stilbenes (yuccaols A, B, C, D, and E). These phenolics have anti-inflammatory activity: they are inhibitors of the nuclear transcription factor NF-κB, which stimulates synthesis of inducible nitric oxide synthase (iNOS), which causes formation of the inflammatory agent nitric oxide.

Phenolic constituents isolated from yucca bark — including resveratrol, trans-3,3',5,5'-tetrahydroxy-4'-methoxystilbene, and the yuccaols — have been shown in vitro to possess antioxidant, radical scavenging, iNOS expression inhibitory, and platelet aggregation inhibitory effects. A phenolic-rich fraction from yucca bark and its main phenolic constituents were shown to inhibit COX-1, COX-2, and LTB4 formation by 5-LOX in vitro.

It has been suggested that the antioxidant and anti-inflammatory properties are mainly generated through free radical scavenging activity, the inhibition of arachidonic acid metabolism, and the decrease in TNF-α, IL-6, and iNOS.

Saponins have diverse biological effects including anti-protozoal activity. It has been postulated that saponins may have anti-arthritic properties by suppressing intestinal protozoa which may have a role in joint inflammation.

Antioxidant Mechanisms

Yucca genus phytochemicals have the capacity to eliminate oxidative stress through the upregulation of antioxidant enzymes HO-1, GPx, CAT, and SOD, as well as by reducing the concentration of MPO and iNOS. The free radical scavenging activity of many Yucca genus phytochemicals reduces the concentration of oxidative molecules such as MDA.

The yuccaols (D and E), along with resveratrol, trans-3,3',5,5'-tetrahydroxy-4'-methoxystilbene, yuccaols A–C, yuccaone A, and larixinol, were assayed for antioxidant activity using the Trolox Equivalent Antioxidant Capacity (TEAC) assay and the coupled oxidation of β-carotene and linoleic acid, with significant activities exhibited in both tests.

Anti-platelet Mechanisms

Resveratrol, trans-3,3',5,5'-tetrahydroxy-4'-methoxystilbene, and yuccaols A and C isolated from Y. schidigera bark were investigated for effects on oxidative stress in resting and activated blood platelets. Tested phenolics (1–25 µg/mL) reduced the level of reactive oxygen species and inhibited the generation of free radicals in blood platelets activated by thrombin (p < 0.05).

Antimicrobial Mechanisms

The antimicrobial constituents of Y. schidigera were identified as three butanol-extractable 5β-spirostan-3β-ol saponins. The benefits of supplementing livestock diets with Y. schidigera extracts have been partly attributed to inhibition of selected gut microbes; although these saponins inhibited microbial growth at low cell densities, their impact was associated with adsorption to the microbes and they had no effect on dense microbial populations.

A saponin fraction from the stems of Yucca schidigera exhibited potent growth-inhibitory activities against certain food-deteriorating yeasts, film-forming yeasts, and dermatophytic yeasts and fungi.

5. Scientific Evidence by Area of Use

5.1 Arthritis and Joint Inflammation

Yucca schidigera is a medicinal plant which may have beneficial effects in the prevention and treatment of arthritis. Active components include steroidal saponins and polyphenolics such as resveratrol and yuccaols.

Human/Clinical Evidence: The only direct studies of anti-arthritic effects of yucca in humans are those of Bingham, who reported that symptoms of pain and swelling in arthritic patients were relieved by consumption of yucca tablets. Bingham's work was reported in an obscure journal and has apparently not been recognized as valid by the arthritis research community. Nevertheless, Bingham's reports led to widespread use of yucca products for treatment and prevention of arthritis not only in humans but also in horses and dogs.

One double-blind, placebo-controlled trial reported in 1975 concluded that the use of yucca reduces arthritis symptoms (both osteoarthritis and rheumatoid arthritis). This report found that the oral administration of daily doses of a yucca saponin extract was effective and well-tolerated for the treatment of various arthritic conditions, with these patients also showing significant reductions in blood pressure and serum cholesterol levels, and a reduction in the incidence of migraine headaches from baseline.

Despite the addition of yucca extracts to equine joint supplement preparations and their use in human arthritis treatment based on a few poor-quality studies from the 1970s, no modern clinical trials exist to support the use of yucca as an anti-inflammatory agent. Yucca phenolics are anti-oxidants and free-radical scavengers which may aid in suppressing reactive oxygen species that stimulate inflammatory responses, though further studies on the anti-arthritic effects of Yucca schidigera remain warranted.

Evidence Strength: Weak. The human evidence rests on a small number of old, methodologically limited studies from the 1970s. No rigorous, adequately powered modern clinical trials have been published. Mechanistic rationale exists from in vitro studies, but this has not translated into validated clinical results.

5.2 Cholesterol and Lipid Metabolism

Human/Clinical Evidence: Kim et al. (2003) evaluated the hypocholesterolemic effect of Y. schidigera and Quillaja saponaria extract pills (6:4 ratio) in humans (n = 51), administering 300 mg of the treatment three times daily for 4 weeks. The results of this study showed that this preparation significantly reduced total cholesterol and LDL levels in the blood plasma of hypercholesterolemic patients without significant changes in HDL levels.

Taking 0.9 mg of the blend (6:4, v:v) of the resulting filtrates per day for 4 weeks resulted in decreases in total and LDL cholesterol levels in blood plasma of hypercholesterolemic patients with enhancement in gastrointestinal symptoms.

Evidence Strength: Preliminary. The Kim et al. (2003) trial is a double-blind, placebo-controlled study in humans and is the best available clinical evidence in this area; however, the study used a combined extract of Y. schidigera and Quillaja saponaria, making it impossible to attribute the effect to yucca alone. The sample size was modest, and replication in independent larger trials has not been published.

5.3 Blood Pressure

A study investigated the effects of dietary supplementation of Yucca schidigera extract (YSE) on blood pressure, antioxidant activity, and biochemical parameters in L-NAME-induced hypertensive rats. The study was performed on 18 male Sprague-Dawley rats divided into 3 groups; YSE (125 mg/kg diet) plus L-NAME-treated rats had significantly lower mean arterial blood pressure (MABP) compared to L-NAME-treated rats alone.

Evidence Strength: Preclinical only (animal model). No human clinical trials specifically addressing yucca and blood pressure have been published. The observation of reduced blood pressure in the early 1975 Bingham trial was a secondary and uncontrolled finding.

5.4 Antioxidant Activity

Yuccaols D and E, along with resveratrol, yuccaols A–C, yuccaone A, and larixinol, were assayed for antioxidant activity using the TEAC assay and the autoxidation assay. The significant activities exhibited by the phenolic fraction and its constituents in both tests show the potential use of Y. schidigera as a source of antioxidant principles.

A 2023 systematic review published in Antioxidants comprehensively analyzed the antioxidant and anti-inflammatory properties of phytochemicals found in the Yucca genus, but noted that despite the historical use and popular notion of these antioxidant and anti-inflammatory properties, there is a limited amount of research on this genus.

Evidence Strength: Mechanistic and in vitro evidence is well-established. Translational human clinical trials validating systemic antioxidant benefits are lacking.

5.5 Anti-platelet and Cardiovascular Effects

The most mentioned activity in the literature for Yucca schidigera is the anti-platelet effect. Platelets are specialized blood cells that play an important role in inflammation and are capable of upregulating leukocyte functions and releasing proinflammatory cytokines. Alcoholic extract from Yucca schidigera has been reported to significantly decrease the various steps of thrombin-platelet activation.

Researchers have found that resveratrol, a compound found in yucca extract as well as in red wine, inhibits the aggregation or clumping of blood platelets, suggesting that yucca extract may be useful in preventing blood clots.

Evidence Strength: Preliminary, confined to in vitro and ex vivo platelet studies. No clinical trials in humans have established cardiovascular endpoints.

5.6 Antimicrobial and Antifungal Activity

The inhibitory activity on key enzymes of arachidonate metabolism observed in various studies might contribute to the explanation of the anti-inflammatory and antiplatelet effects observed for Y. schidigera and its phenolic constituents. Saponins present in Yucca plants have been tested in separate studies and shown properties such as cytotoxic, phytotoxic, antifungal, molluscicidal, and anti-inflammatory activity.

Evidence Strength: Predominantly in vitro. No human clinical trials of yucca as an antimicrobial agent have been conducted.

5.7 Neuroprotective Effects

Y. schidigera contains spiro-flavostilbenoids (derivatives of resveratrol and naringenin) which have potent in vitro anti-inflammatory, antioxidant, and moderate cholinesterase inhibitory activities. To date, these compounds have not been tested in vivo for the treatment of neurodegenerative diseases.

Evidence Strength: Very preliminary. Evidence is restricted to in vitro studies and one zebrafish model; no human data exist.

5.8 Blood Glucose and Diabetes

In a study of diabetic rats, Y. schidigera reduced glucose levels, increased insulin levels, improved high-density lipoprotein cholesterol levels, and exerted antioxidant effects.

Evidence Strength: Preclinical only (animal model). No controlled human trials on blood glucose management with yucca have been published.

6. Body Systems and Health Areas Associated with Yucca

• Musculoskeletal system: Traditional and early clinical use for arthritis (both osteoarthritis and rheumatoid arthritis), joint inflammation, rheumatism, and gout.
• Cardiovascular system: Studied in relation to cholesterol reduction, blood pressure regulation, and anti-platelet/anti-thrombotic activity.
• Immune and inflammatory system: In vitro inhibition of NF-κB, COX-1, COX-2, iNOS, and pro-inflammatory cytokines (TNF-α, IL-6).
• Gastrointestinal system: Traditionally used for digestive complaints; saponins have been studied for effects on gut microbiota and intestinal motility.
• Skin and integumentary system: Topical traditional uses for sores, inflammation, dandruff, hair loss, and skin diseases.
• Nervous system: Preliminary in vitro evidence for cholinesterase inhibition; traditional use for headaches.
• Endocrine system: Animal studies on blood glucose and insulin regulation.

7. Dosage Forms and Reported Dosages

Whole yucca plant powder is available in tablet form; however, there are no clinical trials upon which to base firm dosing recommendations.

The standard dosage reported in the supplement literature is 2 to 4 tablets of concentrated yucca saponins daily.

In the clinical studies that used a yucca saponin extract, tablets were taken three times daily, usually with or after meals.

In the Kim et al. (2003) human cholesterol trial, the dosage administered was 300 mg of a combined Y. schidigera and Quillaja saponaria extract (6:4 ratio) three times daily for 4 weeks in 51 hypercholesterolemic participants.

In the rat hypertension study, yucca schidigera extract was administered at a dose of 125 mg/kg of diet over a 4-week study period.

8. Safety Considerations and Interactions

Regulatory Status

The commercial extracts of Y. schidigera are approved by the FDA as GRAS (Generally Recognized as Safe) and are widely used as animal and human food additives. Yucca powder and yucca extract derived from Yucca schidigera have been given FDA GRAS status.

Gastrointestinal Effects

Yucca can cause loose stools at higher amounts — several times higher than the recommended amounts. Saponins may cause dose-dependent gastrointestinal distress, especially in raw plant form. In controlled clinical trials using yucca tablets, mild and transient complaints were reported in about 9% of patients, and unfavorable gastrointestinal effects were reported in about 4%.

Hemolytic Potential

Yucca and other saponins can cause red blood cells to burst (hemolysis) in test tubes; the level to which this occurs when the saponins are taken orally is uncertain.

Allergic and Sensitization Reactions

Ornamental use of yucca plants is associated with a high incidence of allergic rhinitis. A case report describes contact urticaria and sensitization to Yucca gigantea.

Mineral Absorption

Yucca may interfere with the body's ability to absorb fat-soluble vitamins.

Potential Estrogenic Activity

Yucca may have slight estrogen-like actions due to its steroidal saponin content.

Long-term Safety

Limited data are available regarding the toxicity of yucca saponins, and the effect of long-term ingestion is not well characterized. Since yucca has rarely been studied in a scientific setting, it is not known whether it is safe in children, pregnant or lactating women, or people with a history of severe kidney or liver diseases, heart disease, or cancer.

Drug Interactions

No drug interactions with yucca are well documented. Given the presence of compounds with COX-inhibiting and anti-platelet activity (resveratrol, yuccaols), there is a theoretical basis for caution in combination with anticoagulant or antiplatelet medications, though this has not been evaluated in clinical studies.

References

• Nakamura S, et al. "Antiyeast steroidal saponins from Yucca schidigera (Mohave yucca), a new anti-food-deteriorating agent." Chemical and Pharmaceutical Bulletin, 2000. PubMed PMID: 10757713.
• Piacente S, Pizza C, Oleszek W. "Saponins and phenolics of Yucca schidigera Roezl: Chemistry and bioactivity." Phytochemistry Reviews, 2005.
• Cheeke PR, et al. "Antimicrobial saponins of Yucca schidigera and the implications of their in vitro properties for their in vivo impact." Journal of Agricultural and Food Chemistry, 2000.
• Luo Y, et al. "Spirostane-Type Saponins Obtained from Yucca schidigera." Molecules, 2018. PMC6016961.
• Identification and Structural Analysis of Spirostanol Saponin from Yucca schidigera. PMC7504267.
• Cheeke PR, Piacente S, Oleszek W. "Anti-inflammatory and anti-arthritic effects of Yucca schidigera: A review." Journal of Inflammation, 2006. PMC1440857.
• Piacente S, et al. "Yucca schidigera bark: phenolic constituents and antioxidant activity." Journal of Natural Products, 2004. PubMed PMID: 15165156.
• Oleszek W, et al. "Resveratrol and other phenolics from the bark of Yucca schidigera Roezl." Journal of Agricultural and Food Chemistry, 2001.
• Olas B, et al. "Inhibition of oxidative stress in blood platelets by different phenolics from Yucca schidigera Roezl. bark." PubMed PMID: 12831950.
• Culhuac EB, et al. "Antioxidant and Anti-Inflammatory Properties of Phytochemicals Found in the Yucca Genus." Antioxidants, 2023. PMC10044844.
• Neuroprotective Effect of Yucca schidigera Bark Phenolic Fractions, Yuccaol B and Gloriosaol A on Scopolamine-Induced Memory Deficits in Zebrafish. PMC9227830.
• Structure, Bioactivity and Analytical Methods for the Determination of Yucca Saponins. PMC8433717.
• Kim SW, et al. "Hypocholesterolemic property of Yucca schidigera and Quillaja saponaria extracts in human body." Archives of Pharmacal Research, 2003.
• Drugs.com Natural Products database: Yucca. Reviewed 2026.
• Yucca schidigera — ScienceDirect Topics overview.
• U.S. National Library of Medicine, Native Voices: Yucca — Mescalero Apache Healing Plant.
• Elucidation of the Metabolite Profile of Yucca gigantea and Assessment of Its Anti-Inflammatory Activities. PMC8878216.